Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.
The FDA has approved the first proteolysis-targeting chimera for any oncologic indication. Vepdegestrant (Veppanu, Arvinas ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Newspoint on MSN
Essential information on anti-rabies vaccination after dog bites
Understanding the Anti-Rabies Vaccine Anti-Rabies Vaccine: The anti-rabies vaccine is crucial for individuals who have been ...
FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.
FDA approval covers ER-positive/HER2-negative metastatic disease with ESR1 mutations after ≥1 endocrine line, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results